Summary
Beigene, Ltd.'s (ONC) third quarter 2020 filing shows a significant increase in total assets, largely driven by substantial growth in cash and cash equivalents and short-term investments. Revenue grew by 81.6% year-over-year for the quarter, primarily due to strong performance of internally developed products like tislelizumab and BRUKINSA®, along with initial sales of XGEVA®. However, the company continues to report substantial net losses, with research and development (R&D) and selling, general, and administrative (SG&A) expenses increasing significantly year-over-year. The company successfully raised substantial capital through a registered direct offering in July 2020, bolstering its liquidity position to over $4.7 billion in cash, cash equivalents, and short-term investments as of September 30, 2020. The company's strategic collaborations, particularly with Amgen, are progressing, with significant upfront payments and a co-development funding commitment contributing to the financial landscape. However, challenges persist, including the suspension of ABRAXANE® sales in China and potential impacts from the COVID-19 pandemic on clinical trial recruitment and commercial operations. Despite the ongoing net losses, the substantial cash reserves provide a runway for continued investment in R&D and commercial expansion.
Financial Highlights
54 data points| Revenue | $91.08M |
| Cost of Revenue | $21.12M |
| Gross Profit | $69.96M |
| R&D Expenses | $349.07M |
| SG&A Expenses | $160.84M |
| Operating Expenses | $531.22M |
| Operating Income | -$440.14M |
| Interest Expense | $4.14M |
| Net Income | -$426.62M |
| EPS (Basic) | $-0.37 |
| Shares Outstanding (Basic) | 1.15B |
| Shares Outstanding (Diluted) | 1.15B |
Key Highlights
- 1Total assets grew substantially to $5.57 billion from $1.61 billion year-over-year, driven by a significant increase in cash and short-term investments.
- 2Total revenues for the three months ended September 30, 2020, increased by 81.6% to $91.1 million compared to the prior year period, primarily due to strong product sales.
- 3Net loss attributable to BeiGene, Ltd. widened to $425.2 million for the three months ended September 30, 2020, compared to $307.4 million in the prior year period, reflecting increased R&D and SG&A expenses.
- 4Research and Development (R&D) expenses increased by 47.3% to $349.1 million for the quarter, largely due to collaboration agreement fees and co-development expenses.
- 5Selling, General, and Administrative (SG&A) expenses increased by 53.2% to $160.8 million for the quarter, driven by expansion of commercial organizations and increased professional fees.
- 6The company raised substantial capital through a registered direct offering in July 2020, resulting in net proceeds of approximately $2.07 billion.
- 7Cash, cash equivalents, and restricted cash at the end of the period totaled $1.47 billion, with an additional $3.25 billion in short-term investments, providing ample liquidity.